Eden Research plc Change of Nominated Adviser and Broker (9289R)
November 01 2023 - 2:00AM
UK Regulatory
TIDMEDEN
RNS Number : 9289R
Eden Research plc
01 November 2023
1 November 2023
Eden Research
("Eden" or "the Company")
Change of Nominated Adviser and Broker
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on
sustainable biopesticides and plastic-free formulation technology
for use in the global crop protection, animal health and consumer
products industries, announces that, following the completion of
the all share merger between Cavendish Securities plc (previously
named Cenkos Securities plc) and Cavendish Financial plc
(previously named finnCap Group plc), as a consequence of internal
reorganisation within the Cavendish Group, the Company has changed
its Nominated Adviser and Broker from Cavendish Securities plc to
Cavendish Capital Markets Limited
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Cavendish Capital Markets Limited (Nominated
advisor and broker)
Giles Balleny / George Lawson (corporate
finance)
Michael Johnson (sales) 020 7220 0500
Hawthorn Advisors (Financial PR)
Simon Woods eden@hawthornadvisors.com
Felix Meston
Notes to Editors:
Eden Research is the only UK-listed company focused on
biopesticides for sustainable agriculture. It develops and supplies
innovative biopesticide products and natural microencapsulation
technologies to the global crop protection, animal health and
consumer products industries.
Eden's products are formulated with terpene active ingredients,
based on natural plant defence metabolites. To date, they have been
primarily used on high-value fruits and vegetables, improving crop
yields and marketability, with equal or better performance when
compared with conventional pesticides. Eden has two products
currently on the market:
Based on plant-derived active ingredients, Mevalone(R) is a
foliar biofungicide which initially targets a key disease affecting
grapes and other high-value fruit and vegetable crops. It is a
useful tool in crop defence programmes and is aligned with the
requirements of integrated pest management programmes. It is
approved for sale in a number of key countries whilst Eden and its
partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.
Cedroz(TM) is a bionematicide that targets free living nematodes
which are parasitic worms that affect a wide range of high-value
fruit and vegetable crops globally. Cedroz is registered for sale
on two continents and Eden's commercial collaborator, Eastman
Chemical, is pursuing registration and commercialisation of this
important new product in numerous countries globally.
Eden's Sustaine(R) encapsulation technology is used to harness
the biocidal efficacy of naturally occurring chemicals produced by
plants (terpenes) and can also be used with both natural and
synthetic compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally-derived, plastic-free,
biodegradable micro-spheres derived from yeast. It is one of the
only viable, proven and immediately registerable solutions to the
microplastics problem in formulations requiring encapsulation.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN. It was awarded the London Stock Exchange
Green Economy Mark in January 2021, which recognises London-listed
companies that derive over 50% of their total annual revenue from
products and services that contribute to the global green economy.
Eden derives 100% of its total annual revenues from sustainable
products and services.
For more information about Eden, please visit:
www.edenresearch.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPDFLFXXBLLFBX
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024